Opigolix

Opigolix

Clinical data
Other names	ASP-1707
Routes of administration	By mouth
Drug class	GnRH modulator; GnRH antagonist; Antigonadotropin
Identifiers
IUPAC name (2R)-N'-[5-[3-(2,5-difluorophenyl)-2-(1,3-dihydrobenzimidazol-2-ylidene)-3-oxopropanoyl]-2-fluorophenyl]sulfonyl-2-hydroxypropanimidamide
CAS Number	912587-25-8 Y
PubChem CID	11977994
UNII	VQ6CK0CITA
KEGG	D11351
Chemical and physical data
Formula	C25H19F3N4O5S
Molar mass	544.51 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H](O)/C(N)=N/S(=O)(=O)c1cc(C(=O)C(C(=O)c2cc(F)ccc2F)=C2Nc3ccccc3N2)ccc1F
InChI InChI=1S/C25H19F3N4O5S/c1-12(33)24(29)32-38(36,37)20-10-13(6-8-17(20)28)22(34)21(23(35)15-11-14(26)7-9-16(15)27)25-30-18-4-2-3-5-19(18)31-25/h2-12,30-31,33H,1H3,(H2,29,32)/t12-/m1/s1 Key:CWNLBPBIFALUQD-GFCCVEGCSA-N

Opigolix (INN, USAN; developmental code name ASP-1707) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which was under development by Astellas Pharma for the treatment of endometriosis and rheumatoid arthritis. It was also under investigation for the treatment of prostate cancer. It reached phase II clinical trials for both endometriosis and rheumatoid arthritis prior to the discontinuation of its development in April 2018.

See also

• Gonadotropin-releasing hormone receptor § Antagonists

External links

• Opigolix - AdisInsight